The therapeutic application of Dalacin C 2% (Clindamycin Phosphate vaginal cream) is used in the management of specific localized bacterial infections. The medication is indicated for the management of Bacterial Vaginosis (BV), a condition where functional stability becomes affected. This anti-bacterial therapy is considered relevant when short-term symptomatic assistance is needed to address the underlying localized issue.

It is applied across domains where additional symptomatic support is needed in conditions involving episodic or fluctuating manifestations, and is commonly used to help with symptoms that interfere with daily functioning, such as abnormal discharge, unpleasant genital malodor, and localized irritation.

“This treatment assists with maintaining functional stability and contributes to improved day-to-day comfort during symptomatic periods.”

---

Quick Fact: Symptom Management for Bacterial Vaginosis

Category	Therapeutic Focus
Primary Condition	Symptomatic Bacterial Vaginosis (BV)
Key Symptoms Relevant	Abnormal discharge, malodor, and localized discomfort
Patient Benefit	Supports the easing of symptom fluctuations and contributes to improved comfort
Clinical Context	Applied in scenarios requiring additional management of discomfort

Regulatory References

1. DailyMed: Clindamycin Phosphate Vaginal Cream Indications

Who can and cannot use Dalacin C 2%?

The eligibility for Dalacin C 2% (Clindamycin Phosphate Vaginal Cream) is strictly defined by regulatory documentation, establishing clear rules for approved populations, restricted use, and contraindications.

Eligibility Status	Applicable Populations
Generally Permitted	Non-pregnant adult and older adult females, and pregnant women in their second and third trimesters.
Absolute Contraindication	Individuals with a known history of hypersensitivity to clindamycin, lincomycin, or any components of the cream. Individuals with a history of specific bowel conditions, including regional enteritis, ulcerative colitis, or antibiotic-associated colitis.
Restricted/Unestablished	Pediatric patients (safety and efficacy are not established before menstruation). Pregnant women in the first trimester (use only if clearly needed). Breastfeeding mothers (a regulatory decision is required to discontinue nursing or treatment).

The official labeling classifies the use of this cream as strictly forbidden for individuals with a history of certain severe gastrointestinal conditions or known lincosamide allergy, which represents an absolute prohibition. For all other populations, use is conditional on age or physiological status, with restricted use defined for pre-menarche and early pregnancy.

Interactions with Other Medicines and Products

The official regulatory information regarding Dalacin C 2% (Clindamycin 2% Vaginal Cream) details specific interactions that relate to systemic effects from absorption and physical compatibility with certain products.

Pharmacodynamic Interactions

Clindamycin, the active ingredient, is known to possess neuromuscular blocking properties, even when administered locally with limited systemic absorption. Due to this characteristic:

• Neuromuscular Blocking Agents: The actions of other medicinal products classified as neuromuscular blocking agents may be enhanced when used concurrently with clindamycin. Use with caution is necessary for patients receiving these agents.

Physical and Barrier Incompatibility

The cream formulation contains excipients, specifically mineral oil, that can compromise the integrity of certain materials, leading to two specific constraints:

• Latex and Rubber Products: The strength of latex or rubber products, such as condoms and vaginal contraceptive diaphragms, may be weakened by contact with the cream.

• Restriction: The use of such latex or rubber barrier contraceptive methods is officially not recommended during treatment with Dalacin C 2% and for a specified duration following the completion of treatment (e.g., typically 72 hours to 5 days, as detailed in product-specific regulatory labeling). This restriction is necessary to maintain the physical barrier's function and prevent failure.

Inhibition of Bacterial Protein Synthesis

The drug's primary mechanism involves the targeted inhibition of protein production in susceptible bacteria. The active molecule, Clindamycin, specifically engages and binds to the 50S ribosomal subunit inside the bacterial cell, causing a physical blockade of the peptidyl transferase center. This highly focused molecular action prevents the formation of peptide bonds, immediately stopping the elongation of the polypeptide chain.

Establishing Bacteriostasis and Limiting Proliferation

The arrest of protein synthesis prevents the bacteria from manufacturing the structural components and enzymes required for growth and division. This suppression of essential life processes induces a state of bacteriostasis, characterized by the inhibition of bacterial multiplication. The mechanism modulates the bacterial life cycle, resulting in the physiological consequence of limiting proliferation at the site of administration.

Mechanism Constraints

The drug’s mechanism of action is functionally contingent on the structural integrity of the bacterial ribosome's binding site. Any molecular alteration or mutation in the 23S ribosomal RNA can weaken Clindamycin’s binding affinity, thereby constraining the mechanism and resulting in reduced inhibition of the translation pathway.

How to Use Dalacin C 2%

This section describes the administration and dosing guidelines for Dalacin C 2% (Clindamycin Phosphate Vaginal Cream, 2%).

---

Administration Scope

Feature	Instruction
Route of Administration	Intravaginal use only.
Dosing Schedule	Standard Multi-Dose: One applicatorful (approximately 5 g of 2% cream, containing 100 mg clindamycin) once daily for 3 to 7 consecutive days.
	Standard Single-Dose: One applicatorful administered as a single dose.
Administration Timing	Applied once daily, generally recommended at bedtime to maximize retention.
Missed-Dose Rule	If a dose is missed, it should be administered as soon as possible, but users must not double the dose to make up for the missed timing.

---

Procedural Contexts and Constraints

The entire prescribed course must be completed regardless of symptom status, in line with general principles for antibiotic regimens. For specific populations, pregnant patients (during the second and third trimesters) are typically directed toward the longer 7-day daily regimen.

A key procedural constraint is the avoidance of certain concomitant products. The use of latex or rubber products (e.g., condoms or diaphragms) and other vaginal products (e.g., douches or tampons) must be suspended during and for a period (such as 5 to 7 days) following treatment due to potential component interactions.

Dalacin C 2%: Research Evidence Overview

Evidence for Use in Symptomatic Bacterial Vaginosis (BV)

The research base for Clindamycin Phosphate vaginal cream primarily includes Randomized Controlled Trials (RCTs). These studies involve groups of participants who are randomly assigned to receive the cream, an inactive control (placebo), or another treatment evaluated in studies. Active-controlled trials have also been conducted, which involve research examining the cream alongside other approved anti-bacterial therapies. These trials were designed to examine patterns in Bacterial Vaginosis (BV), a condition characterized by fluctuating or episodic manifestations. Findings describe patterns observed in the studies regarding clinical and microbiological measures when compared to controls.

How Researchers Measured Study Outcomes

The main focus of research has been to capture short-term symptom changes and temporary physiological imbalance in the localized area. Researchers use standardized measurements such as the Amsel criteria for clinical status and the Nugent score for bacteriological status. Studies monitored patient-reported outcomes describing perceived discomfort, such as changes in discharge, malodor, and localized irritation. This data helps to contextualize how patients reported their experience during the research.

Long-term Follow-up and Evidence Gaps

Research includes observation periods that extend beyond the immediate treatment phase; these periods monitor the condition's potential for return. The typical follow-up durations were limited for many pivotal trials, though some studies tracked patients for longer-term periods, typically up to six months, to assess the potential for recurrence. Findings from these extended studies data show patterns related to the frequency of re-diagnosis, though long-term effects are not fully established beyond these initial follow-up windows.

Evidence in Special Populations and Uncertainties

Most of the foundational studies were observed in non-pregnant adult women. Research also included specific, separate studies to assess use in certain special populations, such as pregnant women (focusing on the second and third trimesters) and adolescent females. However, the evidence is limited or insufficient for subjects aged 65 and over, as this population was not widely included in the key clinical trials. Furthermore, the evidence base includes limited research on the outcomes of use during the first trimester of pregnancy, and research in this specific area data are still emerging.

Key Studies & References

1. Clindamycin Phosphate Vaginal Cream, USP 2% (DailyMed/FDA Labeling)

Common questions about Dalacin C 2% (FAQ)

---

Q: What specific type of bacteria is Dalacin C 2% designed to target?

Official regulatory documents state that the medicine is active against bacteria known to be associated with Bacterial Vaginosis (BV). This includes common BV-related organisms such as Gardnerella vaginalis and certain Bacteroides species. The medication functions by inhibiting the growth and multiplication of these susceptible microorganisms at the site of application.

---

Q: What are the official signs of a serious or severe reaction to Dalacin C 2%?

Official safety information describes the potential risk of severe reactions, including signs of Pseudomembranous Colitis (a serious bowel condition). Official guidance suggests that symptoms such as persistent, watery, or bloody diarrhea, fever, or severe abdominal pain may be signs of a serious reaction. These symptoms, or signs of a severe allergic reaction, should be brought to the attention of a healthcare provider immediately.

---

Q: Are there any long-term effects or risks associated with repeated use of Dalacin C 2%?

Official studies available to regulators generally focus on short-term efficacy and safety during the prescribed course of use. Regulatory documentation notes that formal long-term studies to assess the potential for effects like cancer or impaired fertility have not been performed with the active ingredient, clindamycin. This means data on long-term effects is limited.

---

Q: Where can I find the official prescribing information or patient information leaflet for Dalacin C 2%?

The most complete set of facts about this drug is found in the documents prepared for regulatory bodies. These typically include the Prescribing Information (or Summary of Product Characteristics) for healthcare professionals and the Patient Information Leaflet for users. These documents are provided by the manufacturer and government regulatory agencies.

---

Q: Is Dalacin C 2% described as a treatment for conditions beyond its primary approved indication?

Official regulatory labeling indicates that this specific cream formulation is designated only for the treatment of Bacterial Vaginosis (BV). The use of this medicine for any condition other than BV is not described in the official regulatory documents.

---

Q: Is Dalacin C 2% available without a prescription in any countries?

Official drug labeling and prescribing information in regulated markets classify this product as a prescription-only medication. This designation indicates that the medicine is not generally available to purchase without a prescription from an authorized healthcare professional.

---

Q: Does Dalacin C 2% lose its effectiveness if exposed to heat or direct sunlight?

To maintain the integrity and quality of the cream, official storage instructions state that it must be stored at room temperature, below 25 C (77 F). Official storage instructions advise that the medicine be kept away from direct light and heat, and it must not be frozen.

---

Q: How quickly does Dalacin C 2% typically start to work after initial use?

Regulatory data focuses on how quickly the active ingredient enters the bloodstream rather than when symptoms might start improving. Peak levels of clindamycin in the systemic circulation are usually attained approximately 10 to 14 hours after application. The exact time it takes for clinical benefits to become fully noticeable can vary between individuals.

---

Q: Are there any specific preparatory steps or skin care routines described before applying Dalacin C 2%?

Patient information suggests that washing hands thoroughly with soap and water before and after application is a general hygiene measure for use. This recommendation aligns with basic cleanliness practices for using the applicator.

---

Q: Do side effects associated with Dalacin C 2% usually go away once the course of treatment is finished?

While common local side effects are usually expected to resolve after the course of treatment is completed, the risk of serious, systemic side effects can persist. Official warnings state that conditions like Pseudomembranous Colitis can occur not only during treatment but also after the course is finished.

---

Q: Can other topical products or moisturizers be applied at the same time as Dalacin C 2%?

Official instructions advise against the use of other products inserted into the vagina, such as douches or tampons, during treatment. The product information does not specifically address the concurrent use of external topical products or moisturizers, therefore no statement can be made regarding their use.

---

Q: Does consuming alcohol have an effect on the safety profile or efficacy of Dalacin C 2%?

Official product labeling for clindamycin vaginal cream does not contain an explicit warning or contraindication against consuming alcohol. This lack of an official statement is based on the limited systemic absorption of the cream formulation.

---

Q: What types of interactions are described in official documents regarding Dalacin C 2% and blood thinners?

Regulatory documents describe a potential interaction when clindamycin is used with Vitamin K antagonists (a type of blood thinner, such as warfarin). This combination has been associated with increased coagulation test values and bleeding. Official warnings state that frequent monitoring of blood clotting tests is described as necessary if these medications are used together.

---

Q: Is Dalacin C 2% known to interact with birth control pills?

Official interaction warnings indicate that clindamycin may potentially reduce the effectiveness of certain hormonal contraceptives containing estrogen, such as 'the pill.' This interaction is associated with a potential for a higher risk of unintended pregnancy or breakthrough bleeding.

How to Store and Dispose of Dalacin C 2%

The official instructions for Dalacin C 2% (Clindamycin Phosphate vaginal cream) mandate specific storage conditions to maintain product integrity.

Required Storage Conditions

Requirement	Regulatory Mandate
Temperature	Store below 25 C (seventy-seven degrees Fahrenheit).
Prohibited Environment	Do not freeze the product.
Container	Keep the medicine in its original container.
Child Safety	Store out of the sight and reach of children.

Disposal Requirements

Unused or expired Dalacin C 2% must not be discarded in household trash or via wastewater systems. Disposal of the medicine should be carried out according to local requirements for pharmaceutical waste.